Company intelligence / Profile preview

Naylor Olsen Consulting

Lansdale, Pennsylvania, United Statesrocketreach.co ↗

Ownership: Private
Development stage: Phase 1

Overview

Naylor Olsen Consulting is listed as an institutional affiliation for authors involved in the discovery and preclinical development of KB-0742, an orally bioavailable CDK9 inhibitor currently being investigated in phase 1/2 trials for relapsed or refractory solid tumors. The company's role appears to be scientific or technical consulting within this program rather than direct drug development or sponsorship.

Therapeutic areas: Oncology
Modalities: Small Molecule
Industry: Consulting

Drug pipeline

1 asset

KB-0742

Phase 1

Indications: Solid tumors, Non-Hodgkin lymphoma

Partnerships

Involved with teams working on KB-0742/CDK9 inhibitors, but no formal partnerships disclosed

Beyond the preview

Go deeper on Naylor Olsen Consulting.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naylor Olsen Consulting.

Explore the full profile